IL22 and colonic neoplasm: Interestingly, constitutive deletion of the IL-22 antagonist molecule IL-22BP in mice does not result in more tumor formation in steady state conditions but in the context of chronic colitis the unrestrained IL-22 signaling results in increased incidence of colon tumors.